series-a
Stage
1
Investors
About
Develops TELOBLOCK, an antisense nucleotide therapy that inhibits the DNA damage response specifically at short or damaged telomeres to prevent telomere-induced cellular senescence; active in preclinical models for telomere biology disorders (e.g., pulmonary fibrosis, bone marrow failure) and ex-vivo enhancement of hematopoietic cells.
Explore TAG Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.